0001127602-22-022782.txt : 20220921
0001127602-22-022782.hdr.sgml : 20220921
20220921165059
ACCESSION NUMBER: 0001127602-22-022782
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220919
FILED AS OF DATE: 20220921
DATE AS OF CHANGE: 20220921
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Basil Michelle L
CENTRAL INDEX KEY: 0001699629
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14041
FILM NUMBER: 221256822
MAIL ADDRESS:
STREET 1: HAEMONETICS CORPORATION
STREET 2: 400 WOOD ROAD
CITY: BRAINTREE
STATE: MA
ZIP: 02184
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HAEMONETICS CORP
CENTRAL INDEX KEY: 0000313143
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 042882273
STATE OF INCORPORATION: MA
FISCAL YEAR END: 0401
BUSINESS ADDRESS:
STREET 1: 125 SUMMER STREET
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 7818487100
MAIL ADDRESS:
STREET 1: 125 SUMMER STREET
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2022-09-19
0000313143
HAEMONETICS CORP
HAE
0001699629
Basil Michelle L
125 SUMMER STREET
BOSTON
MA
02110
1
EVP and General Counsel
Common Stock
2022-09-19
4
M
0
3464
38.43
A
38859
D
Common Stock
2022-09-19
4
M
0
4213
41.64
A
43072
D
Common Stock
2022-09-19
4
M
0
1011
56.57
A
44083
D
Common Stock
2022-09-19
4
S
0
11448
78.36
D
32635
D
Non-qualified Stock Option (Right to Buy)
38.43
2022-09-19
4
M
0
3464
0
D
2018-03-06
2024-03-06
Common Stock
3464
0
D
Non-qualified Stock Option (Right to Buy)
41.64
2022-09-19
4
M
0
4213
0
D
2018-06-06
2024-06-06
Common Stock
4213
0
D
Non-qualified Stock Option (Right to Buy)
56.57
2022-09-19
4
M
0
1011
0
D
2028-05-18
Common Stock
1011
12553
D
Transaction pursuant to an existing 10b5-1 trading plan.
This number includes unvested restricted stock units ("RSUs") previously reported.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.75, inclusive. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.
/s/ Michelle L. Basil
2022-09-21